Get the Stockscreener App
7.52
4.44%
0.32
Pre-market:
7.47
-0.05
-0.66%
Mind Medicine Inc stock is traded at $7.52, with a volume of 953.81K.
It is up +4.44% in the last 24 hours and up +13.77% over the past month.
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
See More
Previous Close:
$7.20
Open:
$7.2
24h Volume:
953.81K
Relative Volume:
0.90
Market Cap:
$555.85M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-3.7789
EPS:
-1.99
Net Cash Flow:
$-64.37M
1W Performance:
-10.42%
1M Performance:
+13.77%
6M Performance:
-7.45%
1Y Performance:
+173.45%
1-Day Range:
$7.03
$7.69
1-Week Range:
$6.70
$9.85
52-Week Range:
$2.61
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MNMD | 7.52 | 555.85M | 11.40B | -95.73M | -64.37M | -1.99 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
Analysts Set Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Price Target at $25.38 - MarketBeat
Generalized Anxiety Disorder Market to Reach New Heights - openPR
MindMed recruits regulatory expert ahead of Phase III trials - The Pharma Letter
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer - BioSpace
MindMed Appoints Former Karuna Executive to Lead Phase 3 Regulatory Strategy | MNMD Stock News - StockTitan
(MNMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's What Happened - MarketBeat
Stock Traders Purchase Large Volume of Call Options on Mind Medicine (MindMed) (NASDAQ:MNMD) - MarketBeat
COMMODORE CAPITAL LP Acquires Shares in Mind Medicine Inc - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions - Yahoo Finance
Mind Medicine Mindmed Inc (MNMD-Q) QuotePress Release - The Globe and Mail
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
MindMed (MNMD) to Present at Major Healthcare Investor Conferences in London, Florida | MNMD Stock News - StockTitan
Mind Medicine (MindMed)'s (MNMD) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mind Medicine: No News = Good News (NASDAQ:MNMD) - Seeking Alpha
Adam Stanecki on Mind Medicine with Charles Kovess11 November 2023 - imdb
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... By GuruFocus - Investing.com Canada
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Stron - GuruFocus.com
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... - Yahoo Finance
Mind Medicine's Triple-Digit Gains And The Recent CorrectionExcitement Or Anxiety On The Horizon? - RTTNews
MindMed Advances Phase 3 Trials in Mental Health - TipRanks
Certain Restricted Stock Units of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
Certain Common Stock of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
MindMed Reports Third Quarter 2024 Financial Results and Business Updates - Business Wire
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 10.1%What's Next? - MarketBeat
(MNMD) Trading Report - Stock Traders Daily
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate (NASDAQ:MNMD) - Seeking Alpha
Mind Medicine (MindMed) (MNMD) to Release Quarterly Earnings on Thursday - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
MNMDMind Medicine (MindMed) Inc. Common Shares Latest Stock News & Market Updates - StockTitan
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update - The Globe and Mail
FDA is said to see “path forward” for ecstasy-based drug (DRUG:NASDAQ) - Seeking Alpha
MindMed announces exchange agreement with investors By Investing.com - Investing.com
Bright Minds rally ends as psychedelic stocks extend volatility - MSN
Bright Minds stock cools amid psychedelic volatility (DRUG:NASDAQ) - Seeking Alpha
(MNMD) Investment Analysis and Advice - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Coverage Initiated at Leerink Partners - MarketBeat
Mind Medicine assumed with an Outperform at Leerink - Yahoo Finance
Stroke-recovery device using brain-computer interface receives FDA market authorization | WashU Medicine - WashU Medicine
Trend Tracker for (MNMD) - Stock Traders Daily
"TNT Radio" Jeff Ghaemaghamy on Mind Medicine with Charles Kovess28 January 2024 (Podcast Episode 2024)News - imdb
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
MindMed's SWOT analysis: psychedelic stock's potential in anxiety treatment - Investing.com
Marshall Wace LLP Has $15.58 Million Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Mind Medicine's chief medical officer sells shares worth over $41,000 - Investing.com India
MindMed executive sells over $26k in company stock By Investing.com - Investing.com South Africa
Mind Medicine's chief medical officer sells shares worth over $41,000 By Investing.com - Investing.com UK
Generalized Anxiety Disorder Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, MindMed, VistaGen Pharma - Barchart
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):